Literature DB >> 2527537

The effect of acute ACE inhibition on atrial natriuretic peptide.

C J Doorenbos1, P van Brummelen.   

Abstract

1. The effect of acute angiotensin converting enzyme (ACE) inhibition on the plasma concentrations of atrial natriuretic peptide (ANP) was investigated in a single-blind placebo controlled crossover study in healthy volunteers. 2. Intravenous infusion of 2 mg cilazaprilat resulted in a significant and short lasting inhibition of ACE as evidenced by a decrease of plasma angiotensin II and an increase in plasma renin activity. 3. When compared with placebo cilazaprilat lowered diastolic pressure and increased heart rate significantly. 4. No effect of cilazaprilat was found on plasma ANP levels, suggesting that angiotensin II does not mediate ANP release.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527537      PMCID: PMC1379754          DOI: 10.1111/j.1365-2125.1989.tb03488.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man.

Authors:  F H Katz; P Romfh; J A Smith
Journal:  J Clin Endocrinol Metab       Date:  1975-01       Impact factor: 5.958

2.  Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man.

Authors:  J McMurray; A D Struthers
Journal:  Clin Sci (Lond)       Date:  1988-04       Impact factor: 6.124

3.  Effect of alpha-human atrial natriuretic peptide in low renin essential hypertension and primary aldosteronism.

Authors:  F Mantero; S Rocco; F Pertile; G Carpenè; F Fallo; L Leone; M Boscaro
Journal:  Clin Exp Hypertens A       Date:  1987

4.  Effects of captopril on plasma atrial natriuretic polypeptide and the renin angiotensin system in rats.

Authors:  H Iwao; K Fukui; A Yamamoto; T Shoji; Y Abe
Journal:  Clin Exp Hypertens A       Date:  1987

5.  Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; P Goldberg; G Martin; P Sever
Journal:  Clin Sci (Lond)       Date:  1988-02       Impact factor: 6.124

6.  Effect of chronic treatment with angiotensin I converting enzyme inhibitors on circulating atrial natriuretic polypeptide in spontaneously hypertensive rats.

Authors:  M Kohno; K Yasunari; T Matsuura; Y Kanayama; K Takaori; K Murakawa; T Takeda
Journal:  Clin Exp Hypertens A       Date:  1987

7.  Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study.

Authors:  J P Chalmers; L M Wing; M J West; A J Bune; J M Elliott; M J Morris; M D Cain; J R Graham; D O Southgate
Journal:  Aust N Z J Med       Date:  1986-08

8.  Effect of angiotensin I converting enzyme inhibition on circulating atrial natriuretic peptide in humans.

Authors:  F E Mann; R E Lang; M Leidig; E Ritz
Journal:  Klin Wochenschr       Date:  1986

9.  Effects of atrial natriuretic peptide (ANP) during converting enzyme inhibition.

Authors:  P Hansell; H R Ulfendahl
Journal:  Acta Physiol Scand       Date:  1987-07

10.  Enalapril attenuates natriuresis of atrial natriuretic factor in humans.

Authors:  C A Gaillard; H A Koomans; E J Mees
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

View more
  2 in total

Review 1.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  Clinical pharmacology of cilazapril.

Authors:  C H Kleinbloesem; P van Brummelen; R J Francis; U W Wiegand
Journal:  Drugs       Date:  1991       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.